Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Clinical trial on enzymatic agent Salizolis
ISRCTN ISRCTN32740751
ClinicalTrials.gov identifier
Public title Clinical trial on enzymatic agent Salizolis
Scientific title
Acronym SALIZOLIS
Serial number at source N/A
Study hypothesis Not provided at time of registration
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Lithuania
Disease/condition/study domain Wounds
Participants - inclusion criteria Patients with acute and chronic wounds containing necrotic tissue (thermal and chemical burns, frostbites, trophic ulcers, injuries of truncal and limb, injuries of wrist and hand, injuries of tarsus and foot, varicosis of lower limbs with ulcers and inflammation, foot ulcers, pressure sores, infections on dermal and hypodermal tissue and other purulent inflammations).

Inclusion criteria:
1. Older than 18 years

Participants - exclusion criteria 1. Children under the age of 18
2. Pregnant women
3. Soldiers of active service
4. Incurable patients
5. Patients with mental disorder
6. Patients dependent on drugs and alcohol
7. Subjects incapable of giving consent
8. Subjects disagree with participation in clinical trial
Anticipated start date 01/12/2004
Anticipated end date 31/12/2005
Status of trial Completed
Patient information material
Target number of participants 30
Interventions The randomised and controlled, single blind and parallel group study will be carried out on two groups. Each group consists of 15 patients.
Patients of group A are being treated according to the current standards of therapy. The wounds will be self-purged out of necrotic tissues.
Patients of group B are being treated according to the new regimen under investigation - enzymatic agent Salizolis. Necrotic tissue of the wounds will be purged out by enzymatic agent.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Sixth framework programme horizontal research activities involving small and medium sized enterprises (SMEs) co-operative research project - Ultimate Pressure Dressing System for the Management of Venous Ulcers (European Union)
Trial website
Publications
Contact name Dr  Rimdeika  Rytis
  Address Kaunas Medical University Hospital
Department of Surgery
Division of Plastic Surgery and Burns
Eiveniu str. 2
  City/town Kaunas
  Zip/Postcode 50009
  Country Lithuania
  Tel +370 37 326083
  Fax +370 37 326601
  Email rimdeika@kmu.lt
Sponsor JSC Biocentras (Lithuania)
  Address Graiciuno str. 10
  City/town Vilnius
  Zip/Postcode 02241
  Country Lithuania
  Tel +370 5 2661313
  Fax +370 5 2602454
  Email biocentras@biocentras.lt
  Sponsor website: http://www.biocentras.lt/about_en.html
Date applied 09/11/2004
Last edited 03/03/2008
Date ISRCTN assigned 08/12/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central